257 related articles for article (PubMed ID: 37561274)
1. Cyclosporine as Therapy for Traumatic Brain Injury.
Hansson MJ; Elmér E
Neurotherapeutics; 2023 Oct; 20(6):1482-1495. PubMed ID: 37561274
[TBL] [Abstract][Full Text] [Related]
2. Copenhagen Head Injury Ciclosporin Study: A Phase IIa Safety, Pharmacokinetics, and Biomarker Study of Ciclosporin in Severe Traumatic Brain Injury Patients.
Kelsen J; Karlsson M; Hansson MJ; Yang Z; Fischer W; Hugerth M; Nordström CH; Åstrand R; Keep MF; Kilbaugh T; Wang KKW; Møller K; Juhler M; Elmér E
J Neurotrauma; 2019 Dec; 36(23):3253-3263. PubMed ID: 31210099
[TBL] [Abstract][Full Text] [Related]
3. Synaptic Mitochondria Sustain More Damage than Non-Synaptic Mitochondria after Traumatic Brain Injury and Are Protected by Cyclosporine A.
Kulbe JR; Hill RL; Singh IN; Wang JA; Hall ED
J Neurotrauma; 2017 Apr; 34(7):1291-1301. PubMed ID: 27596283
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic window analysis of the neuroprotective effects of cyclosporine A after traumatic brain injury.
Sullivan PG; Sebastian AH; Hall ED
J Neurotrauma; 2011 Feb; 28(2):311-8. PubMed ID: 21142667
[TBL] [Abstract][Full Text] [Related]
5. Continuous Infusion of Phenelzine, Cyclosporine A, or Their Combination: Evaluation of Mitochondrial Bioenergetics, Oxidative Damage, and Cytoskeletal Degradation following Severe Controlled Cortical Impact Traumatic Brain Injury in Rats.
Kulbe JR; Singh IN; Wang JA; Cebak JE; Hall ED
J Neurotrauma; 2018 Jun; 35(11):1280-1293. PubMed ID: 29336204
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Diffusion Tensor Imaging and Fluid Based Biomarkers in a Large Animal Trial of Cyclosporine in Focal Traumatic Brain Injury.
Karlsson M; Yang Z; Chawla S; Delso N; Pukenas B; Elmér E; Hugerth M; Margulies SS; Ehinger J; Hansson MJ; Wang KKW; Kilbaugh TJ
J Neurotrauma; 2021 Jun; 38(13):1870-1878. PubMed ID: 33191835
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A attenuates acute mitochondrial dysfunction following traumatic brain injury.
Sullivan PG; Thompson MB; Scheff SW
Exp Neurol; 1999 Nov; 160(1):226-34. PubMed ID: 10630207
[TBL] [Abstract][Full Text] [Related]
8. Tailored Reconstituted Lipoprotein for Site-Specific and Mitochondria-Targeted Cyclosporine A Delivery to Treat Traumatic Brain Injury.
Chen L; Song Q; Chen Y; Meng S; Zheng M; Huang J; Zhang Q; Jiang J; Feng J; Chen H; Jiang G; Gao X
ACS Nano; 2020 Jun; 14(6):6636-6648. PubMed ID: 32464051
[TBL] [Abstract][Full Text] [Related]
9. Targets of Neuroprotection and Review of Pharmacological Interventions in Traumatic Brain Injury.
Hiskens MI
J Pharmacol Exp Ther; 2022 Aug; 382(2):149-166. PubMed ID: 35644464
[TBL] [Abstract][Full Text] [Related]
10. Progesterone neuroprotection: The background of clinical trial failure.
Schumacher M; Denier C; Oudinet JP; Adams D; Guennoun R
J Steroid Biochem Mol Biol; 2016 Jun; 160():53-66. PubMed ID: 26598278
[TBL] [Abstract][Full Text] [Related]
11. Cyclosporine A for neuroprotection: establishing dosing guidelines for safe and effective use.
Cook AM; Whitlow J; Hatton J; Young B
Expert Opin Drug Saf; 2009 Jul; 8(4):411-9. PubMed ID: 19548859
[TBL] [Abstract][Full Text] [Related]
12. Medical treatment and neuroprotection in traumatic brain injury.
Clausen T; Bullock R
Curr Pharm Des; 2001 Oct; 7(15):1517-32. PubMed ID: 11562296
[TBL] [Abstract][Full Text] [Related]
13. An overview of new and novel pharmacotherapies for use in traumatic brain injury.
Vink R; Nimmo AJ; Cernak I
Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):919-21. PubMed ID: 11703396
[TBL] [Abstract][Full Text] [Related]
14. Investigational agents for treatment of traumatic brain injury.
Xiong Y; Zhang Y; Mahmood A; Chopp M
Expert Opin Investig Drugs; 2015 Jun; 24(6):743-60. PubMed ID: 25727893
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial neuroprotection in traumatic brain injury: rationale and therapeutic strategies.
Yokobori S; Mazzeo AT; Gajavelli S; Bullock MR
CNS Neurol Disord Drug Targets; 2014; 13(4):606-19. PubMed ID: 24168363
[TBL] [Abstract][Full Text] [Related]
16. Post-injury administration of the mitochondrial permeability transition pore inhibitor, NIM811, is neuroprotective and improves cognition after traumatic brain injury in rats.
Readnower RD; Pandya JD; McEwen ML; Pauly JR; Springer JE; Sullivan PG
J Neurotrauma; 2011 Sep; 28(9):1845-53. PubMed ID: 21875332
[TBL] [Abstract][Full Text] [Related]
17. Newer pharmacological approaches for antioxidant neuroprotection in traumatic brain injury.
Hall ED; Wang JA; Miller DM; Cebak JE; Hill RL
Neuropharmacology; 2019 Feb; 145(Pt B):247-258. PubMed ID: 30086292
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporin A preserves mitochondrial function after traumatic brain injury in the immature rat and piglet.
Kilbaugh TJ; Bhandare S; Lorom DH; Saraswati M; Robertson CL; Margulies SS
J Neurotrauma; 2011 May; 28(5):763-74. PubMed ID: 21250918
[TBL] [Abstract][Full Text] [Related]
19. A review of laboratory and clinical data supporting the safety and efficacy of cyclosporin A in traumatic brain injury.
Lulic D; Burns J; Bae EC; van Loveren H; Borlongan CV
Neurosurgery; 2011 May; 68(5):1172-85; discussion 1185-6. PubMed ID: 21307793
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
